Not sure which EpiVax service is right for you?

Immunogenicity risk assessment is not just a regulatory checkbox; it’s an adaptive process spanning discovery through commercialization where each phase informs the next.  

EpiVax’s predictive tools, in vitro assays, and expert consulting make it possible to anticipate and mitigate risk, not just measure it. When integrated into later-stage activities, they provide a data-driven foundation for regulatory confidence and clinical success, no matter the modality or construct.  

Ready to turn immunogenicity insights into a smarter strategy?

Explore our offerings based on your unique candidate’s modality, current phase, or by specific analysis capabilities to learn how EpiVax can support your pipeline’s success.